Literature DB >> 9337927

Outcome and prognostic factors in the surgical treatment of spinal dural arteriovenous fistulas. A long-term study.

L Tacconi1, B C Lopez Izquierdo, L Symon.   

Abstract

From a total of 78 patients surgically treated for a spinal dural arteriovenous fistula, in whom long-term follow-up was available, 25 have been reviewed. Their outcome at different postoperative stages and the long-term prognostic factors is discussed. Excision or coagulation of the nidus, as well as disconnection of the draining vein offers better results in the long-term than clipping of the draining vein alone. Prolonged duration of symptoms and poor functional status before surgical treatment adversely affect the long-term outcome. Age at the time of surgery did not influence outcome in this study. In the long-term all patients tended to show a moderate, but definite functional decline. This is unlikely to be due entirely to recanalization and may represent a more generalized haemodynamic abnormality of the cord together with the effects of age on the original damage.

Entities:  

Mesh:

Year:  1997        PMID: 9337927     DOI: 10.1080/02688699746078

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


  21 in total

1.  Secondary clinical deterioration after successful embolization of a spinal dural arteriovenous fistula: a plea for prophylactic anticoagulation.

Authors:  J Knopman; W Zink; A Patsalides; H A Riina; Y P Gobin
Journal:  Interv Neuroradiol       Date:  2010-07-19       Impact factor: 1.610

2.  N-butyl 2-cyanoacrylate embolization of spinal dural arteriovenous fistulae: CT evaluation, technical features, and outcome prognosis in 26 cases.

Authors:  Remy Guillevin; J N Vallee; E Cormier; D Lo; D Dormont; J Chiras
Journal:  AJNR Am J Neuroradiol       Date:  2005-04       Impact factor: 3.825

3.  Single center experience with treatment of spinal dural arteriovenous fistulas.

Authors:  Neriman Özkan; Ilonka Kreitschmann-Andermahr; Sophia Luise Goerike; Karsten Henning Wrede; Bernadette Kleist; Klaus-Peter Stein; Oliver Gembruch; Ibrahim Erol Sandalcioglu; Isabel Wanke; Ulrich Sure
Journal:  Neurosurg Rev       Date:  2015-07-17       Impact factor: 3.042

4.  N-butyl 2-cyanoacrylate embolization of spinal dural arteriovenous fistulae.

Authors:  J K Song; Y P Gobin; G R Duckwiler; Y Murayama; J G Frazee; N A Martin; F Viñuela
Journal:  AJNR Am J Neuroradiol       Date:  2001-01       Impact factor: 3.825

Review 5.  [Diagnostic work-up and therapy of spinal vascular malformations: an update].

Authors:  S Eicker; B Turowski; H-J Steiger; D Hänggi
Journal:  Nervenarzt       Date:  2010-06       Impact factor: 1.214

6.  The use of magnetic resonance imaging in predicting the clinical outcome of spinal arteriovenous fistula.

Authors:  Dong Ah Shin; Keun Young Park; Gyu Yeul Ji; Seong Yi; Yoon Ha; Seoung Woo Park; Do Heum Yoon; Keung Nyun Kim
Journal:  Yonsei Med J       Date:  2015-03       Impact factor: 2.759

7.  [Spinal syndrome triggered by a lumbar spinal av malformation. A case report].

Authors:  F Ahlhelm; A Nabhan; J Kelm; U Dorenbeck; L T Sova; W Reith
Journal:  Nervenarzt       Date:  2005-12       Impact factor: 1.214

8.  Peripheral spinal cord hypointensity on T2-weighted MR images: a reliable imaging sign of venous hypertensive myelopathy.

Authors:  R W Hurst; R I Grossman
Journal:  AJNR Am J Neuroradiol       Date:  2000-04       Impact factor: 3.825

9.  Long-term outcomes after surgical and endovascular treatment of spinal dural arteriovenous fistulae.

Authors:  Toru Sasamori; Kazutoshi Hida; Shunsuke Yano; Takeshi Asano; Toshitaka Seki; Kiyohiro Houkin
Journal:  Eur Spine J       Date:  2015-03-24       Impact factor: 3.134

10.  Long-term outcome of a multidisciplinary concept of spinal dural arteriovenous fistulae treatment.

Authors:  Camillo Sherif; Andreas Gruber; Gerhard Bavinzski; Harald Standhardt; Georg Widhalm; Daniel Gibson; Bernd Richling; Engelbert Knosp
Journal:  Neuroradiology       Date:  2007-11-20       Impact factor: 2.804

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.